cafepharmaOct 23, 2023
Roche pays $7.1B to Roivant for rights to Telavant’s IBD candidate-- Latest ESMO news from Merck, Ambrx, AstraZeneca --Pfizer beats out GSK with FDA nod for first 5-in-1 meningitis shot -- See more on our front page news http://bit.ly/w28kSd #roche #ibd #roivant #mergersandacquisitions #esmo #merck #astrazeneca #pfizer #gsk #vaccines #fda #meningitis #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Cafepharma

Cafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more.

Cafepharma
DrBob, 🧠 MechanicAug 27, 2023

From biotech booster to #Republican contender (or Con Man): the rise of Vivek #Ramaswamy

“as GSK had privately predicted, the medicine was a flop and in 2017 it failed clinical trials, causing Axovant’s shares to collapse. #Roivant’s holding company structure insulated it from the worst of the crash but other investors lost millions of dollars. Earlier this year, shareholders of Axovant, since renamed SioGene, voted to liquidate and dissolve the company.”
@FinancialTimes
https://www.ft.com/content/6b9689a6-0dec-41b9-a5d0-50ceba4b3bd4?desktop=true&segmentId=7c8f09b9-9b61-4fbb-9430-9208a9e233c8#myft:notification:daily-email:content

From biotech booster to Republican contender: the rise of Vivek Ramaswamy

Presidential candidate makes polling gains by capitalising on image as successful businessman

Financial Times